Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on April 30, 2026.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Smallcap 250 and 2.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs reported audited consolidated financial results for FY26 ending March 31, 2026. Revenue from operations grew 12.25% to INR 27,629 million from INR 24,614 million in FY25. Profit after tax increased 3.57% to INR 5,098 million from INR 4,922 million. The Board declared a final dividend of INR 4 per share (40% on face value), bringing total dividend for FY26 to INR 20.5 per share. The company acquired 100% stake in Shahbazkers Diagnostic Centre Private Limited and approved incorporation of a wholly-owned subsidiary in Dubai. Key leadership reappointments include Dr. Arvind Lal as Executive Chairman for 5 years. An exceptional item of INR 301 million was recorded due to Labour Codes implementation. The statutory auditor Deloitte issued an unmodified (clean) opinion on the financial statements.
Strong revenue growth of 12.25% with PAT growth of 3.57% indicates healthy business expansion, though margin compression is visible. Dividend declaration and acquisition activity signal continued shareholder value creation and expansion strategy.